ICU Medical, Inc. — Q3 2012 Form 10-Q
Reporting period: Three and nine months ended September 30, 2012; financial statements are unaudited. ICU Medical develops, manufactures and sells medical devices for infusion therapy, critical care and oncology. Figures below are in U.S. dollars; financial-statement amounts are rounded to millions unless otherwise stated.
Financial performance and position
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Total revenue | $81.4M | $76.5M | $234.2M | $225.7M |
| Gross profit / margin | $40.7M / 50% | $35.6M / 47% | $114.7M / 49% | $106.4M / 47% |
| Operating income / margin | $17.5M / 22% | $13.3M / 18% | $42.5M / 18% | $39.5M / 17% |
| Net income | $12.2M | $9.3M | $28.9M | $26.8M |
| Diluted EPS | $0.82 | $0.65 | $1.98 | $1.89 |
For the first nine months, operating cash flow was $40.9M, versus $36.1M a year earlier. Capital expenditures were $13.2M; cash used in investing activities was $32.2M, including net purchases of investment securities. Financing activities provided $19.4M, mainly from employee stock-option exercises and employee stock purchases.
At September 30, cash and cash equivalents were $127.5M and investment securities were $76.8M, totaling $204.3M, up $44.3M from year-end 2011. Current assets were $312.6M and current liabilities $28.9M. The filing reports no debt on the balance sheet. The company said existing cash, investments and expected operating cash flows should fund operations for at least the next 12 months.
Changes and operating drivers
- Q3 revenue increased 6% year over year; nine-month revenue increased 4%. Growth was led by infusion therapy, while critical care declined.
- Q3 infusion therapy sales rose 14% to $57.2M, including higher CLAVE and custom infusion-set sales. Nine-month infusion therapy sales rose 9% to $159.6M.
- Critical care sales fell 12% in Q3 to $13.0M and 10% for the nine-month period to $42.4M. Management cited competition, lower unit sales, prior price reductions and foreign exchange.
- Oncology sales increased 10% in both periods: to $7.5M in Q3 and $21.0M year to date. Other product sales declined, partly because the Orbit diabetes product line was sold in November 2011.
- Gross margin improved year over year. Management attributed the increase to product mix and favorable Mexican peso exchange rates.
- Nine-month R&D expense rose to $8.4M from $6.4M, primarily due to higher project-related spending. SG&A was $63.9M versus $63.0M; the 2011 comparison included a $2.0M Long-Term Retention Plan expense.
Outlook, risks and unusual items
- Management estimated 2012 capital expenditures of $16M–$21M, SG&A at approximately 26.5% of revenue, R&D at approximately 3.6% of revenue, and an effective tax rate of approximately 33%. These are estimates, not guarantees.
- Management expected modest growth in infusion therapy and oncology, and a decline in critical care sales, while noting that actual results could differ. International sales face European economic weakness and currency effects; the euro’s decline reduced nine-month international sales by an estimated $3.1M.
- Hospira accounted for 41% of revenue in the first nine months and 44% in Q3; it also represented 37% of accounts receivable at quarter-end. The company depends on this customer and related distribution arrangements.
- Competition, customer concentration, product-development and commercialization execution, international conditions and currency movements are key disclosed risks. The company does not hedge its foreign-currency exposures. Management reported no material changes to previously disclosed risk factors.
- A 2011 settlement generated $2.5M of operating-expense credit in the prior-year nine-month period; there was no comparable 2012 credit. ICU Medical’s patent-infringement case against RyMed remained pending: a jury had found infringement and patent validity, while a court ruling on RyMed’s estoppel defense and a damages proceeding remained outstanding.
- The company had $28.1M remaining under its $40.0M share-repurchase authorization and made no repurchases in the first nine months of 2012. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter.
Investor verification points
- Assess the company’s substantial dependence on Hospira, including the durability of its commercial agreements and the concentration of receivables.
- Verify whether infusion-therapy growth can offset ongoing critical-care declines and competitive pricing pressure.
- Track receivables and collection timing: accounts receivable rose $9.4M from year-end, and management cited longer international collection periods.
- Review the assumptions behind margin improvement, particularly product mix and Mexican peso movements, and the company’s unhedged currency exposure.
- Monitor the RyMed litigation outcome and any effect on potential damages or costs; the filing does not provide a clear value for any possible recovery.